All Data
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2021
Details:
Dr. Reddy’s has initiated the process with the Drugs Controller General of India (DCGI) for Emergency Use Authorization (EUA) of the well-studied human adenoviral vector-based platform vaccine candidate, Sputnik V.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Global Response Aid FZCO
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2021
Details:
The data from the Kuwait CVD-04-CD-001 study involving moderate to severe COVID-19 hospitalized patients did not show a statistically significant difference for the primary endpoint (i.e., time to sustained hypoxia resolution) for Avigan vs. placebo.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 15, 2021
Details:
The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, doubleblind, parallel-group, placebo-controlled study in India.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Reeqonus
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Appili Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
Dr. Reddy's Canada has filed an application with Health Canada on behalf of the consortium for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate Covid-19 in adult patients.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
In a meeting, Subject Expert Committee (SEC) on COVID-19 at the CDSCO, deliberated on the application and asked the firm to resubmit a revised protocol as it was not satisfied with the data of Phase II trials submitted by the company.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2020
Details:
Upon regulatory approval in India, RDIF will supply to drugmaker Dr Reddy's 100 million doses of the vaccine, the firm said last month.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
Offering a portfolio of products & services including APIs, CMO services, generics, biosimilars & differentiated formulations.
